Clément Karine, van den Akker Erica L T, Argente Jesús, Beales Phil, Cetiner Metin, Dubern Béatrice, Farooqi Sadaf, Gouronc Aurélie, Kühnen Peter, Le Beyec Johanne, Lebreton Louis, Meeker David, Müller Hermann L, Muller Jean, Poitou Christine, Sleiman Patrick, Vaisse Christian, Wabitsch Martin, Young Jacques, Dollfus Hélène
INSERM, Nutrition and Obesity: Systemic Approaches, NutriOmics, Research Unit, Sorbonne Université, Paris, France.
Assistance Publique-Hôpitaux de Paris, Nutrition Department, Pitié-Salpêtrière Hospital, Paris, France.
Clin Obes. 2025 Oct;15(5):e70029. doi: 10.1111/cob.70029. Epub 2025 Jul 31.
A total of 150 clinicians and researchers representing 19 countries came together in person and online to participate in the highly anticipated 2nd International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE), held on 13-15 December 2023 in Paris, France. Building on the success of the inaugural event in 2022, this gathering served as a pivotal platform for attendees to delve into the latest scientific and clinical developments in hyperphagia and early-onset obesity caused by rare melanocortin-4 receptor (MC4R) pathway disease. The central objective of the meeting was to explore the complexities of MC4R pathway-related diseases and generate opportunities for collaborative dialogue among delegates for the advancement of this field. The event unfolded across three distinct sessions, with a dedicated focus on monogenic MC4R pathway disease, Bardet-Biedl syndrome (BBS) and hypothalamic obesity, together with a discussion on the future of the field. Additionally, the agenda featured three insightful workshops designed to facilitate in-depth discussions. One workshop focused on the genetics of monogenic MC4R pathway diseases, another scrutinised the genetics of BBS and the final workshop examined patient management through the exploration of clinical cases. As we reflect on the wealth of information disseminated and the collaborative spirit that permeated the meeting, it becomes clear that IMPROVE 2023 was not merely an assembly of professionals; it was a forum where the future of research in rare MC4R pathway diseases and patient care took centre stage. Here, we encapsulate the key insights, discussions, and initiatives that emerged from this important meeting.
来自19个国家的150名临床医生和研究人员齐聚一堂，通过线下和线上的方式，参加了备受期待的第二届肥胖症相关通路国际会议：愿景与证据（IMPROVE），该会议于2023年12月13日至15日在法国巴黎举行。此次会议以2022年首届会议的成功为基础，为与会者提供了一个关键平台，以深入探讨由罕见的黑皮质素-4受体（MC4R）通路疾病引起的食欲亢进和早发性肥胖的最新科学和临床进展。会议的核心目标是探索与MC4R通路相关疾病的复杂性，并为代表们开展合作对话创造机会，以推动该领域的发展。活动分为三个不同的环节，专门聚焦于单基因MC4R通路疾病、巴德-比德尔综合征（BBS）和下丘脑性肥胖，并对该领域的未来进行了讨论。此外，议程还安排了三场富有洞察力的研讨会，以促进深入讨论。一场研讨会聚焦于单基因MC4R通路疾病的遗传学，另一场审视了BBS的遗传学，最后一场研讨会则通过临床病例探讨来研究患者管理。当我们回顾会议上传播的丰富信息以及弥漫其中的合作精神时，很明显，2023年的IMPROVE不仅仅是专业人士的集会；它是一个论坛，在这个论坛上，罕见MC4R通路疾病的研究未来和患者护理成为了核心主题。在此，我们总结此次重要会议产生的关键见解、讨论内容和倡议。
